SAN 61

Drug Profile

SAN 61

Alternative Names: SAN-161; SAN-61

Latest Information Update: 20 Mar 2013

Price : $50

At a glance

  • Originator Sanomune
  • Class Antidementias; Recombinant proteins
  • Mechanism of Action Amyloid beta-protein inhibitors; Amyloid inhibitors; Glycogen synthase kinase 3 inhibitors; Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Alzheimer's disease; Neurological disorders

Most Recent Events

  • 20 Mar 2013 No development reported - Preclinical for Neurological disorders in Canada (PO)
  • 20 Mar 2013 No development reported - Preclinical for Neurological disorders in Canada (Intranasal)
  • 20 Mar 2013 No development reported - Preclinical for Alzheimer's disease in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top